Karen Kelly

15PUBLICATIONS
130CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 04, 2025
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.

Philip C Mack, Mary W Redman, Hanna Tukachinsky

|Oct 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.

Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson

|Jan 26, 2024
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.

Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose

|Sep 07, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Riha Vaidya, Joseph M Unger, Lu Qian

|May 26, 2023
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).

Shirish M Gadgeel, Jieling Miao, Jonathan W Riess

Pageof 3